Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials

Area of Science:

• Virology
• Immunology
• Epidemiology

Background:

• COVID-19 vaccines are known to reduce severe disease and mortality.
• Vaccine efficacy in reducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission is an area of ongoing research.
• Viral load (VL) at diagnosis is a potential marker for SARS-CoV-2 infectiousness.

Purpose of the Study:

• To evaluate the association between COVID-19 vaccination and SARS-CoV-2 viral load at the time of diagnosis.
• To assess the impact of different vaccine types on viral load.
• To understand the potential effect of vaccines on viral transmission.

Main Methods:

• Analysis of data from four Phase 3 randomized, placebo-controlled vaccine trials conducted between July 2020 and July 2021.
• Measurement of SARS-CoV-2 viral load (VL) in participants at the time of COVID-19 diagnosis.
• Statistical evaluation of the association between vaccination status and VL for NVX-CoV2373, mRNA-1273, AZD1222, and Ad26.COV2.S vaccines.

Main Results:

• Significant VL reductions were observed for NVX-CoV2373 (2.78 log10 copies/mL) and mRNA-1273 (2.12 log10 copies/mL).
• No significant VL reduction associations were found for AZD1222 (0.59 log10 copies/mL) or Ad26.COV2.S (0.23 log10 copies/mL).
• These findings were observed during a period when ancestral SARS-CoV-2 strains predominated.

Conclusions:

• Certain COVID-19 vaccines, specifically NVX-CoV2373 and mRNA-1273, may decrease SARS-CoV-2 transmission by reducing viral load.
• The association between vaccination and viral load varied by vaccine type.
• Further research is needed to confirm these findings and their implications for public health strategies.